Appeal No. 95-4791
Application 08/034,849
unbound HIV virus present in the subject is inactivated
by the treatment thereby inhibiting infection of
undamaged
cells.
11. A method according to claim 1, wherein the
concentration of T-cells and NK cells are increased
after administration of said chlorite matrix.
The examiner appears to be satisfied by the evidence of
record that (1) the method appellant claims meets the
practical utility requirements of 35 U.S.C. § 101, and (2) the
description of the claimed invention in the specification
would have enabled one skilled in the art to make and use the
full scope of the method claimed in the manner provided by the
first paragraph of 35 U.S.C. § 112. We review the merits of
the final rejection under 35 U.S.C. § 103 in that light.
Discussion
1. Claim interpretation
The claimed process of parenterally treating HIV
infections requires parenteral administration of an
inhibition-effective amount of a chemically-stabilized
chlorite matrix comprising an isotonic solution containing
about 5 to about 100 mMol ClO per liter of isotonic solution2-
to a subject in need of treatment for HIV infections. We hold
that the phrase “HIV infections” in appellant’s claims means
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007